{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:42:34Z","timestamp":1747165354176,"version":"3.40.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jmdjournal.org","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Molecular Diagnostics"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jmoldx.2024.01.010","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T10:01:16Z","timestamp":1707991276000},"page":"399-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-5835","authenticated-orcid":false,"given":"Becky","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hnin","family":"Aung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adayapalam","family":"Nandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghusoon","family":"Abdulrasool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9129-8783","authenticated-orcid":false,"given":"Chiyan","family":"Lau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmoldx.2024.01.010_bib1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib2","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2016.71.0806","article-title":"Clinical implications of genetic mutations in myelodysplastic syndrome","volume":"35","author":"Kennedy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1200\/JCO.2016.70.7968","article-title":"Genomics of myeloproliferative neoplasms","volume":"35","author":"Zoi","year":"2017","journal-title":"J Clin Oncol"},{"year":"2017","first-page":"29","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid tissues. WHO Classification of Tumours","key":"10.1016\/j.jmoldx.2024.01.010_bib4"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib6","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib9","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/ijms18081618","article-title":"Clinical outcomes and co-occurring mutations in patients with RUNX1-mutated acute myeloid leukemia","volume":"18","author":"Khan","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib11","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.3390\/ijms19113492","article-title":"Minimal\/measurable residual disease monitoring in NPM1-mutated acute myeloid leukemia: a clinical viewpoint and perspectives","volume":"19","author":"Forghieri","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib12","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib14","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","article-title":"GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib15","doi-asserted-by":"crossref","first-page":"32065","DOI":"10.18632\/oncotarget.7028","article-title":"Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jmoldx.2018.09.009","article-title":"Clinical utility of a next-generation sequencing panel for acute myeloid leukemia diagnostics","volume":"21","author":"Alonso","year":"2019","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41408-018-0148-6","article-title":"Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use","volume":"8","author":"Bacher","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2017.11.003","article-title":"Standards and guidelines for validating next-generation sequencing bioinformatics pipelines: a joint recommendation of the Association for Molecular Pathology and the College of American Pathologists","volume":"20","author":"Roy","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ejhg.2015.226","article-title":"Guidelines for diagnostic next-generation sequencing","volume":"24","author":"Matthijs","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib21","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib22","first-page":"121","article-title":"Genetic landscape of acute myeloid leukemia interrogated by next-generation sequencing: a large cancer center experience","volume":"15","author":"Hussaini","year":"2018","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib23","doi-asserted-by":"crossref","first-page":"30084","DOI":"10.18632\/oncotarget.8310","article-title":"Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms","volume":"7","author":"Bartels","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ajcp\/aqw222","article-title":"Comparison of the mutational profiles of primary myelofibrosis, polycythemia vera, and essential thrombocytosis","volume":"147","author":"Song","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib25","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib26","article-title":"Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes","volume":"7","author":"Xu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib27","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3390\/genes13040630","article-title":"Technological advances: CEBPA and FLT3 internal tandem duplication mutations can be reliably detected by next generation sequencing","volume":"13","author":"Akabari","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib29","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/s41375-018-0193-y","article-title":"Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs\u221712) from artifact in myeloid malignancies using NGS","volume":"32","author":"Alberti","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.579221","article-title":"Comparison and implications of mutational profiles of myelodysplastic syndromes, myeloproliferative neoplasms, and myelodysplastic\/myeloproliferative neoplasms: a meta-analysis","volume":"10","author":"Wan","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib31","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.3324\/haematol.2017.183160","article-title":"The mutational landscape of 18 investigated genes clearly separates four subtypes of myelodysplastic\/myeloproliferative neoplasms","volume":"103","author":"Meggendorfer","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib32","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.3324\/haematol.2019.219352","article-title":"Genomics of therapy-related myeloid neoplasms","volume":"105","author":"Kuzmanovic","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib33","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv"},{"key":"10.1016\/j.jmoldx.2024.01.010_bib35","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"}],"container-title":["The Journal of Molecular Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157824000308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525157824000308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T13:20:26Z","timestamp":1746105626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525157824000308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1525157824000308"],"URL":"https:\/\/doi.org\/10.1016\/j.jmoldx.2024.01.010","relation":{},"ISSN":["1525-1578"],"issn-type":[{"type":"print","value":"1525-1578"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analytical Validation of a 37-Gene Next-Generation Sequencing Panel for Myeloid Malignancies and Review of Initial Findings Incorporating Updated 2022 Diagnostic and Prognostic Guidelines","name":"articletitle","label":"Article Title"},{"value":"The Journal of Molecular Diagnostics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmoldx.2024.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}